FR11C0053I1 - - Google Patents
Info
- Publication number
- FR11C0053I1 FR11C0053I1 FR11C0053C FR11C0053I1 FR 11C0053 I1 FR11C0053 I1 FR 11C0053I1 FR 11C0053 C FR11C0053 C FR 11C0053C FR 11C0053 I1 FR11C0053 I1 FR 11C0053I1
- Authority
- FR
- France
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70503—Immunoglobulin superfamily
- C07K14/70521—CD28, CD152
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
- G01N33/502—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
- G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
- G01N33/5047—Cells of the immune system
- G01N33/505—Cells of the immune system involving T-cells
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Immunology (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Biomedical Technology (AREA)
- Molecular Biology (AREA)
- Medicinal Chemistry (AREA)
- Urology & Nephrology (AREA)
- Hematology (AREA)
- General Health & Medical Sciences (AREA)
- Cell Biology (AREA)
- Biochemistry (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Physics & Mathematics (AREA)
- Food Science & Technology (AREA)
- Physics & Mathematics (AREA)
- Toxicology (AREA)
- Biotechnology (AREA)
- Analytical Chemistry (AREA)
- Pathology (AREA)
- Microbiology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Genetics & Genomics (AREA)
- Gastroenterology & Hepatology (AREA)
- Biophysics (AREA)
- Zoology (AREA)
- Transplantation (AREA)
- Peptides Or Proteins (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US57992700A | 2000-05-26 | 2000-05-26 | |
| US21406500P | 2000-06-26 | 2000-06-26 | |
| PCT/US2001/017139 WO2001092337A2 (en) | 2000-05-26 | 2001-05-23 | Soluble ctla4 mutant molecules and uses thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| FR11C0053I1 true FR11C0053I1 (zh) | 2012-01-13 |
| FR11C0053I2 FR11C0053I2 (fr) | 2013-01-11 |
Family
ID=26908652
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| FR11C0053C Active FR11C0053I2 (fr) | 2000-05-26 | 2011-12-07 | Molecules ctla4 mutantes solubles et leurs utilisations |
Country Status (41)
| Country | Link |
|---|---|
| EP (3) | EP1536234B1 (zh) |
| JP (1) | JP4328525B2 (zh) |
| KR (2) | KR100889887B1 (zh) |
| CN (2) | CN1309735C (zh) |
| AR (1) | AR031699A1 (zh) |
| AT (1) | ATE271066T1 (zh) |
| AU (2) | AU6346601A (zh) |
| BE (1) | BE2011C041I2 (zh) |
| BR (1) | BRPI0111191B8 (zh) |
| CA (1) | CA2409748C (zh) |
| CY (2) | CY2011019I1 (zh) |
| CZ (1) | CZ304451B6 (zh) |
| DE (2) | DE60104282T2 (zh) |
| DK (1) | DK1248802T3 (zh) |
| EC (1) | ECSP024365A (zh) |
| EE (2) | EE05458B1 (zh) |
| EG (1) | EG24459A (zh) |
| ES (2) | ES2225549T3 (zh) |
| FR (1) | FR11C0053I2 (zh) |
| GE (1) | GEP20053658B (zh) |
| HK (2) | HK1048126B (zh) |
| HU (2) | HU228137B1 (zh) |
| IL (1) | IL152315A (zh) |
| LT (1) | LT5133B (zh) |
| LU (1) | LU91902I2 (zh) |
| LV (1) | LV12994B (zh) |
| MX (1) | MXPA02011534A (zh) |
| MY (1) | MY136113A (zh) |
| NO (2) | NO330797B1 (zh) |
| PE (1) | PE20011338A1 (zh) |
| PL (1) | PL206267B1 (zh) |
| PT (1) | PT1248802E (zh) |
| RU (1) | RU2283847C2 (zh) |
| SI (1) | SI1248802T1 (zh) |
| SK (1) | SK288131B6 (zh) |
| TR (1) | TR200402703T4 (zh) |
| TW (2) | TWI314933B (zh) |
| UA (1) | UA87432C2 (zh) |
| UY (1) | UY26723A1 (zh) |
| WO (1) | WO2001092337A2 (zh) |
| ZA (1) | ZA200208944B (zh) |
Families Citing this family (49)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6887471B1 (en) | 1991-06-27 | 2005-05-03 | Bristol-Myers Squibb Company | Method to inhibit T cell interactions with soluble B7 |
| US7094874B2 (en) | 2000-05-26 | 2006-08-22 | Bristol-Myers Squibb Co. | Soluble CTLA4 mutant molecules |
| US20040022787A1 (en) | 2000-07-03 | 2004-02-05 | Robert Cohen | Methods for treating an autoimmune disease using a soluble CTLA4 molecule and a DMARD or NSAID |
| ES2667203T3 (es) | 2000-07-03 | 2018-05-10 | Bristol-Myers Squibb Company | Usos de moléculas mutantes de CTL4 solubles |
| DK1397153T3 (da) | 2001-05-23 | 2008-05-26 | Bristol Myers Squibb Co | Fremgangsmåde til beskyttelse af allogent ö-celle-transplantat ved anvendelse af oplöselige CTLA4-mutantmolekyler |
| EP1496931A4 (en) * | 2002-04-19 | 2009-07-01 | Bristol Myers Squibb Co | METHODS OF TREATING AUTOIMMUNE DISEASE USING SOLUBLE CTLA4 MOLECULE AND ARMM OR NSAID |
| DE10232697A1 (de) * | 2002-07-15 | 2004-02-05 | Universitätsklinikum Charité, Medizinische Fakultät der Humboldt-Universität zu Berlin | Verwendung von CD152 zur Behandlung von Autoimmunkrankheiten und Entzündungen |
| JP4541157B2 (ja) | 2002-12-23 | 2010-09-08 | ブリストル−マイヤーズ スクイブ カンパニー | タンパク質を製造するための哺乳類細胞培養法 |
| AU2003303394B2 (en) * | 2002-12-23 | 2009-02-19 | Bristol-Myers Squibb Company | Product quality enhancement in mammalian cell culture processes for protein production |
| PL378879A1 (pl) | 2002-12-30 | 2006-05-29 | Amgen Inc. | Terapia skojarzona z czynnikami kostymulującymi |
| WO2005044188A2 (en) | 2003-10-27 | 2005-05-19 | Amgen Inc. | Compositions and methods to modulate an immune response to an immunogenic therapeutic agent |
| AR058568A1 (es) | 2005-12-20 | 2008-02-13 | Bristol Myers Squibb Co | Metodos para producir una composicion con moleculas ctla4-ig a partir de un medio de cultivo |
| PE20080556A1 (es) | 2005-12-20 | 2008-06-13 | Bristol Myers Squibb Co | Composicion que comprende una poblacion aislada de moleculas ctla4-ig a partir de un medio de cultivo liquido y metodos para su obtencion |
| US7510844B2 (en) | 2006-01-24 | 2009-03-31 | Bristol-Myers Squibb Company | CD86 and CD80 receptor competition assays |
| WO2008005290A2 (en) | 2006-06-29 | 2008-01-10 | The Trustees Of Columbia University In The City Of New York | Methods for testing anti-thrombotic agents |
| GB0620934D0 (en) | 2006-10-20 | 2006-11-29 | Cambridge Antibody Tech | Protein variants |
| MX2009006659A (es) | 2006-12-20 | 2009-10-12 | Mmr Information Systems Inc | Anticuerpos y metodos de elaboracion y uso. |
| EP2385065A1 (en) | 2007-11-01 | 2011-11-09 | Perseid Therapeutics LLC | Immunosuppressive polypeptides and nucleic acids |
| US9493564B2 (en) * | 2008-10-02 | 2016-11-15 | Aptevo Research And Development Llc | CD86 antagonist multi-target binding proteins |
| US9540426B2 (en) * | 2009-10-06 | 2017-01-10 | Bristol-Myers Squibb Company | Mammalian cell culture processes for protein production |
| EP2545073B1 (en) * | 2010-03-12 | 2015-09-30 | AbbVie Biotherapeutics Inc. | Ctla4 proteins and their uses |
| CA2827492A1 (en) | 2011-02-23 | 2012-08-30 | Amgen Inc. | Cell culture media for uvc exposure and methods related thereto |
| WO2013010537A1 (en) | 2011-07-20 | 2013-01-24 | Aarhus Universitet | Method of treating morphea |
| WO2013148049A1 (en) * | 2012-03-29 | 2013-10-03 | The General Hospital Corporation | Recombinant cytotoxic t-lymphocyte-associated protein 4 (ctla4) |
| MX355234B (es) * | 2012-05-11 | 2018-04-11 | Medimmune Ltd | Variantes de antigeno 4 del linfocito t citotoxico (ctla-4). |
| US8735359B2 (en) | 2012-05-24 | 2014-05-27 | Orban Biotech Llc | Combinations of modalities for the treatment of diabetes |
| AU2013284460A1 (en) * | 2012-06-27 | 2015-01-29 | Dmnomore | CTLA4 fusion proteins for the treatment of diabetes |
| US20140112958A1 (en) | 2012-10-24 | 2014-04-24 | Mwm Biomodels Gmbh | Pancreatic islets of transgenic LEA29Y animals for treating diabetes |
| CN104740608A (zh) * | 2013-12-30 | 2015-07-01 | 上海中信国健药业股份有限公司 | 可溶性ctla4分子用于制备治疗类风湿性关节炎药物的用途 |
| BR122020004385B1 (pt) | 2014-01-13 | 2022-10-04 | Amgen Inc | Método para aumentar o teor de glicoforma de alta manose de uma glicoproteína recombinante e método de produção de uma glicoproteína recombinante |
| GB2523399B (en) | 2014-02-25 | 2019-03-13 | Orban Tihamer | A composition comprising ten overlapping peptide fragments of the entire preproinsulin sequence |
| US11384378B2 (en) | 2014-06-04 | 2022-07-12 | Amgen Inc. | Methods for harvesting mammalian cell cultures |
| SG11201704351WA (en) | 2014-12-01 | 2017-06-29 | Amgen Inc | Process for manipulating the level of glycan content of a glycoprotein |
| US10590457B2 (en) | 2015-02-11 | 2020-03-17 | Bristol Myers-Squibb Company | Compositions for cell culture and methods of using the same |
| WO2016168771A2 (en) | 2015-04-17 | 2016-10-20 | Alpine Immune Sciences, Inc. | Immunomodulatory proteins with tunable affinities |
| CA2997947A1 (en) | 2015-09-09 | 2017-03-16 | The Trustees Of Columbia University In The City Of New York | Reduction of er-mam-localized app-c99 and methods of treating alzheimer's disease |
| US11401509B2 (en) | 2015-11-09 | 2022-08-02 | Bristol-Myers Squibb Company | Methods of minimizing glycoprotein agregation in CHO cell production |
| EP3515489A4 (en) * | 2016-09-19 | 2020-05-06 | Oncoimmune, Inc. | CD80 AND CD86 BINDING PROTEIN COMPOSITIONS AND USES THEREOF |
| CN107987153A (zh) * | 2016-10-27 | 2018-05-04 | 广东香雪精准医疗技术有限公司 | 高亲和力的可溶性pd-1分子 |
| EP3612023A4 (en) | 2017-04-20 | 2021-05-12 | Egenesis, Inc. | GENETICALLY MODIFIED ANIMAL PRODUCTION PROCESSES |
| KR20230020022A (ko) | 2017-10-10 | 2023-02-09 | 알파인 이뮨 사이언시즈, 인코포레이티드 | Ctla-4 변이체 면역조절 단백질 및 이의 용도 |
| CN115227824A (zh) * | 2018-11-12 | 2022-10-25 | 中南大学湘雅二医院 | 免疫检查点的抑制剂在制备治疗青光眼和其他眼部免疫损伤机制相关疾病药物中的应用 |
| CN115551530A (zh) | 2019-08-27 | 2022-12-30 | 通尼克斯制药有限公司 | 经修饰的tff2多肽 |
| IL302538A (en) | 2019-12-06 | 2023-07-01 | Regeneron Pharma | Anti-VEGF protein preparations and methods for their production |
| MX2022013812A (es) | 2020-05-08 | 2022-12-15 | Regeneron Pharma | Trampas y mini-trampas de vegf y metodos para el tratamiento de trastornos oculares y cancer. |
| CA3184812A1 (en) | 2020-06-18 | 2021-12-23 | Regeneron Pharmaceuticals, Inc. | Heavy peptide approach to accurately measure unprocessed c-terminal lysine |
| WO2022027013A1 (en) | 2020-07-28 | 2022-02-03 | Seagen Inc. | Methods and systems for producing polypeptides |
| KR20240125949A (ko) | 2021-12-16 | 2024-08-20 | 브리스톨-마이어스 스큅 컴퍼니 | 바이러스 불활성화를 위한 세제 |
| WO2023167863A1 (en) | 2022-03-02 | 2023-09-07 | Regeneron Pharmaceuticals, Inc. | Manufacturing process for high titer antibody |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4399216A (en) | 1980-02-25 | 1983-08-16 | The Trustees Of Columbia University | Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials |
| DE69226871T3 (de) | 1991-06-27 | 2009-09-24 | Bristol-Myers Squibb Co. | CTL4A-Rezeptor, ihn enthaltenden Fusionsproteine und deren Verwendung |
| US5851795A (en) * | 1991-06-27 | 1998-12-22 | Bristol-Myers Squibb Company | Soluble CTLA4 molecules and uses thereof |
| US5844095A (en) | 1991-06-27 | 1998-12-01 | Bristol-Myers Squibb Company | CTLA4 Ig fusion proteins |
| US5637481A (en) | 1993-02-01 | 1997-06-10 | Bristol-Myers Squibb Company | Expression vectors encoding bispecific fusion proteins and methods of producing biologically active bispecific fusion proteins in a mammalian cell |
| ZA98533B (en) * | 1997-01-31 | 1999-07-22 | Bristol Myers Squibb Co | Soluble CTLA4 mutant molecules and uses thereof. |
| JP3521382B2 (ja) * | 1997-02-27 | 2004-04-19 | 日本たばこ産業株式会社 | 細胞間接着及びシグナル伝達を媒介する細胞表面分子 |
| GB9809280D0 (en) * | 1998-04-30 | 1998-07-01 | Rpms Technology Ltd | Immunosupression |
| JP2003532370A (ja) * | 1998-10-07 | 2003-11-05 | ミレニアム・ファーマシューティカルズ・インコーポレイテッド | 新規なＴｈ２特異的分子およびその使用方法 |
| ES2667203T3 (es) * | 2000-07-03 | 2018-05-10 | Bristol-Myers Squibb Company | Usos de moléculas mutantes de CTL4 solubles |
-
2001
- 2001-05-23 EP EP04008908.8A patent/EP1536234B1/en not_active Expired - Lifetime
- 2001-05-23 SI SI200130186T patent/SI1248802T1/xx unknown
- 2001-05-23 EP EP01937764A patent/EP1248802B9/en not_active Expired - Lifetime
- 2001-05-23 CZ CZ2002-3892A patent/CZ304451B6/cs unknown
- 2001-05-23 UY UY26723A patent/UY26723A1/es not_active IP Right Cessation
- 2001-05-23 TW TW090112431A patent/TWI314933B/zh not_active IP Right Cessation
- 2001-05-23 SK SK1570-2002A patent/SK288131B6/sk not_active IP Right Cessation
- 2001-05-23 PE PE2001000465A patent/PE20011338A1/es active IP Right Grant
- 2001-05-23 KR KR1020077017691A patent/KR100889887B1/ko active IP Right Grant
- 2001-05-23 TR TR2004/02703T patent/TR200402703T4/xx unknown
- 2001-05-23 ES ES01937764T patent/ES2225549T3/es not_active Expired - Lifetime
- 2001-05-23 AT AT01937764T patent/ATE271066T1/de active
- 2001-05-23 MY MYPI20012427A patent/MY136113A/en unknown
- 2001-05-23 RU RU2002131588/13A patent/RU2283847C2/ru active Protection Beyond IP Right Term
- 2001-05-23 EE EEP200200659A patent/EE05458B1/xx active Protection Beyond IP Right Term
- 2001-05-23 AR ARP010102449A patent/AR031699A1/es active IP Right Grant
- 2001-05-23 PL PL366231A patent/PL206267B1/pl unknown
- 2001-05-23 PT PT01937764T patent/PT1248802E/pt unknown
- 2001-05-23 AU AU6346601A patent/AU6346601A/xx active Pending
- 2001-05-23 CN CNB018101453A patent/CN1309735C/zh not_active Expired - Lifetime
- 2001-05-23 TW TW097137809A patent/TWI319405B/zh not_active IP Right Cessation
- 2001-05-23 JP JP2002500948A patent/JP4328525B2/ja not_active Expired - Lifetime
- 2001-05-23 GE GE4987A patent/GEP20053658B/en unknown
- 2001-05-23 DE DE60104282T patent/DE60104282T2/de not_active Expired - Lifetime
- 2001-05-23 HU HU0302201A patent/HU228137B1/hu active Protection Beyond IP Right Term
- 2001-05-23 AU AU2001263466A patent/AU2001263466C1/en active Active
- 2001-05-23 ES ES04008908T patent/ES2571852T3/es not_active Expired - Lifetime
- 2001-05-23 IL IL152315A patent/IL152315A/en active Protection Beyond IP Right Term
- 2001-05-23 KR KR1020027015946A patent/KR100895134B1/ko active IP Right Grant
- 2001-05-23 EG EG20010548A patent/EG24459A/xx active
- 2001-05-23 UA UA20021210563A patent/UA87432C2/uk unknown
- 2001-05-23 EE EEP201100050A patent/EE05557B1/xx unknown
- 2001-05-23 MX MXPA02011534A patent/MXPA02011534A/es active IP Right Grant
- 2001-05-23 CN CNA2007100840790A patent/CN101255192A/zh active Pending
- 2001-05-23 DK DK01937764T patent/DK1248802T3/da active
- 2001-05-23 BR BR0111191-4 patent/BRPI0111191B8/pt not_active IP Right Cessation
- 2001-05-23 WO PCT/US2001/017139 patent/WO2001092337A2/en not_active Application Discontinuation
- 2001-05-23 CA CA002409748A patent/CA2409748C/en not_active Expired - Lifetime
- 2001-05-23 EP EP15197082.9A patent/EP3029062A1/en not_active Withdrawn
-
2002
- 2002-11-04 ZA ZA200208944A patent/ZA200208944B/en unknown
- 2002-11-13 LT LT2002114A patent/LT5133B/lt not_active IP Right Cessation
- 2002-11-25 NO NO20025656A patent/NO330797B1/no not_active IP Right Cessation
- 2002-11-26 EC EC2002004365A patent/ECSP024365A/es unknown
- 2002-12-19 LV LVP-02-214A patent/LV12994B/en unknown
-
2003
- 2003-01-09 HK HK03100239.8A patent/HK1048126B/zh not_active IP Right Cessation
-
2005
- 2005-06-21 HK HK05105135.0A patent/HK1071931A1/zh not_active IP Right Cessation
-
2011
- 2011-11-10 BE BE2011C041C patent/BE2011C041I2/fr unknown
- 2011-11-16 LU LU91902C patent/LU91902I2/fr unknown
- 2011-12-05 DE DE201112100063 patent/DE122011100063I1/de active Pending
- 2011-12-07 FR FR11C0053C patent/FR11C0053I2/fr active Active
- 2011-12-12 CY CY2011019C patent/CY2011019I1/el unknown
- 2011-12-15 NO NO2011027C patent/NO2011027I1/no not_active IP Right Cessation
-
2013
- 2013-04-12 HU HUS1300012C patent/HUS1300012I1/hu unknown
-
2016
- 2016-06-10 CY CY20161100511T patent/CY1117625T1/el unknown